DM199 for Pregnancy Complications
- Conditions
- PreeclampsiaFetal Growth Restriction (FGR)
- Interventions
- First Posted Date
- 2025-03-13
- Last Posted Date
- 2025-03-13
- Lead Sponsor
- DiaMedica Therapeutics Inc
- Target Recruit Count
- 120
- Registration Number
- NCT06875141
- Locations
- 🇿🇦
Preeclampsia Research Institute, Department of Obstetrics and Gynaecology, Stellenbosch University,, Tygerberg, CapeTown, South Africa
Treatment of Acute Ischemic Stroke (ReMEDy2 Trial)
- Conditions
- Acute StrokeStrokeIschemic Stroke
- Interventions
- Drug: Recombinant human tissue kallikreinOther: Placebo for DM199 Solution for Injection
- First Posted Date
- 2021-10-04
- Last Posted Date
- 2025-05-02
- Lead Sponsor
- DiaMedica Therapeutics Inc
- Target Recruit Count
- 728
- Registration Number
- NCT05065216
- Locations
- 🇺🇸
Ascension Via Christi Hospitals Wichita Inc., Wichita, Kansas, United States
🇺🇸Gulf Health Hospitals d/b/a Thomas Hospital, Fairhope, Alabama, United States
🇺🇸Glendale Adventist Medical Center d/b/a Adventist Health Glendale, Glendale, California, United States
Multiple Doses of DM199 in Patients With Chronic Kidney Disease (REDUX)
- First Posted Date
- 2019-10-11
- Last Posted Date
- 2022-03-31
- Lead Sponsor
- DiaMedica Therapeutics Inc
- Target Recruit Count
- 79
- Registration Number
- NCT04123613
- Locations
- 🇺🇸
IMD Clinical Trials Inc, Los Angeles, California, United States
🇺🇸Elixia at Florida Kidney Physicians-SE, Fort Lauderdale, Florida, United States
🇺🇸Pines Clinical Research-Hollywood, Hollywood, Florida, United States
Study to Assess PK, Safety and Tolerability in Patients With DM and CKD
- Conditions
- Chronic Kidney DiseaseChronic Kidney Disease, Stage 3 (Moderate)Chronic Kidney Disease, Stage 4 (Severe)Diabetes
- Interventions
- First Posted Date
- 2019-01-07
- Last Posted Date
- 2021-09-13
- Lead Sponsor
- DiaMedica Therapeutics Inc
- Target Recruit Count
- 33
- Registration Number
- NCT03795389
- Locations
- 🇺🇸
Clinical Pharmacology of Miami, Hialeah, Florida, United States
🇺🇸Prism Research, Saint Paul, Minnesota, United States
🇺🇸Orlando Clinical Research Center Inc, Orlando, Florida, United States
Evaluation to Assess Safety and Tolerability of DM199 in Subjects With Acute Ischemic Stroke
- Conditions
- Acute Ischemic Stroke
- Interventions
- Other: PlaceboDrug: Recombinant human tissue kallikrein
- First Posted Date
- 2017-09-25
- Last Posted Date
- 2022-03-31
- Lead Sponsor
- DiaMedica Therapeutics Inc
- Target Recruit Count
- 92
- Registration Number
- NCT03290560
- Locations
- 🇦🇺
Lismore Base Hospital, Lismore, New South Wales, Australia
🇦🇺Liverpool Hospital, Liverpool, New South Wales, Australia
🇦🇺John Hunter Hospital, New Lambton Heights, New South Wales, Australia
An Open Label, Phase 1b, Ascending Dose Study of DM199
- Conditions
- Stroke
- Interventions
- Drug: Recombinant human tissue kallikrein
- First Posted Date
- 2016-08-16
- Last Posted Date
- 2017-12-07
- Lead Sponsor
- DiaMedica Therapeutics Inc
- Target Recruit Count
- 36
- Registration Number
- NCT02868996
- Locations
- 🇦🇺
Linear Clinical Research, Perth, Western Australia, Australia
A Study to Evaluate the Safety and Effectiveness of DM199 in Healthy Subjects and Type 2 Diabetes Patients
- First Posted Date
- 2013-05-03
- Last Posted Date
- 2014-12-19
- Lead Sponsor
- DiaMedica Therapeutics Inc
- Target Recruit Count
- 98
- Registration Number
- NCT01845064
- Locations
- 🇳🇱
PRA, Zuidlaren, Netherlands